Apotex
ORG
Apotex
The settlement, with Apotex, of Canada, calls for the companies to pay an undisclosed amount to Apotex and also allows the generic company to sell its version of Plavix beginning in September 2011, eight months before the United States patent is expected to expire. The companies said they would split the payments to Apotex 50-50, adding that they expected to establish reserves this quarter for the minimum estimated amount of the payment. Under the agreement, Apotex will make undisclosed royalty payments to the companies beginning in 2011.